Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations.

Journal: Scientific reports
PMID:

Abstract

Treatment of COVID-19 with a soluble version of ACE2 that binds to SARS-CoV-2 virions before they enter host cells is a promising approach, however it needs to be optimized and adapted to emerging viral variants. The computational workflow presented here consists of molecular dynamics simulations for spike RBD-hACE2 binding affinity assessments of multiple spike RBD/hACE2 variants and a novel convolutional neural network architecture working on pairs of voxelized force-fields for efficient search-space reduction. We identified hACE2-Fc K31W and multi-mutation variants as high-affinity candidates, which we validated in vitro with virus neutralization assays. We evaluated binding affinities of these ACE2 variants with the RBDs of Omicron BA.3, Omicron BA.4/BA.5, and Omicron BA.2.75 in silico. In addition, candidates produced in Nicotiana benthamiana, an expression organism for potential large-scale production, showed a 4.6-fold reduction in half-maximal inhibitory concentration (IC) compared with the same variant produced in CHO cells and an almost six-fold IC reduction compared with wild-type hACE2-Fc.

Authors

  • Katharina Köchl
    Innophore GmbH, 8010, Graz, Austria.
  • Tobias Schopper
    Innophore GmbH, 8010, Graz, Austria.
  • Vedat Durmaz
    Innophore GmbH, 8010, Graz, Austria.
  • Lena Parigger
    Innophore GmbH, 8010, Graz, Austria.
  • Amit Singh
    Innophore GmbH, 8010, Graz, Austria.
  • Andreas Krassnigg
    Innophore GmbH, 8010, Graz, Austria.
  • Marco Cespugli
    Innophore GmbH, 8010, Graz, Austria.
  • Wei Wu
    Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Xiaoli Yang
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Yanchong Zhang
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Welson Wen-Shang Wang
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Crystal Selluski
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Tiehan Zhao
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Xin Zhang
    First Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Caihong Bai
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Leon Lin
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Yuxiang Hu
    Jiangxi Medical College, The First Affiliated Hospital, Nanchang University, Nanchang, China.
  • Zhiwei Xie
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Zaihui Zhang
    SignalChem Lifesciences Corp., 110-13120 Vanier Place, Richmond, BC, V6V 2J2, Canada.
  • Jun Yan
    Department of Statistics, University of Connecticut, Storrs, CT 06269, USA.
  • Kurt Zatloukal
    Medical University of Graz, Graz, Austria.
  • Karl Gruber
    Innophore GmbH, 8010, Graz, Austria.
  • Georg Steinkellner
    Innophore GmbH, 8010, Graz, Austria. georg.steinkellner@innophore.com.
  • Christian C Gruber
    Innophore GmbH, 8010, Graz, Austria. christian.gruber@innophore.com.